Shopping Cart 0
Cart Subtotal
USD 0

Adamas Pharmaceuticals Inc (ADMS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) is a pharmaceutical company that develops and commercializes therapeutics for chronic disorders of the central nervous system. The company's Gocovri, formerly ADS-5102, is an amantadine extended-release (XR) formulation for the treatment for dyskinesia in patients with Parkinson's disease. Gocovri is a high-dose, once-daily indication designed to deliver high level of amantadine in the morning and throughout the day when dyskinesia occurs. Its pipeline includes ADS-5102 for the treatment of wearing OFF, and delaying motor complications in Parkinson's disease; Huntington's chorea; tardive dyskinesia; non-motor disorders, including depression, and anti-psychotic induced weight gain; and Tourette syndrome; and various others indications; and ADS-4101 in Phase 3 for the treatment of partial onset seizures in patients with epilepsy. The company also offers namzaric and namenda XR for the treatment of moderate to severe Alzheimer's disease. Adamas Pharmaceuticals is headquartered in Emeryville, California, the US.

Adamas Pharmaceuticals Inc (ADMS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Equity Offering 11

Adamas Pharma Raises USD143.2 Million in Public Offering of Shares 11

Adamas Pharma Raises USD9.7 Million in Private Placement of Shares 13

Adamas Pharma Plans to Raise up to USD200 Million in Public Offering of Shares 14

Adamas Pharma Raises USD66 Million in Public Offering of Shares 15

Adamas Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 17

Adamas Pharma Completes IPO For USD 48 Million 18

Debt Offering 20

Adamas Pharma Raises USD35 Million in Private Placement of 11% Royalty-Backed Note Due 2026 20

Adamas Pharmaceuticals Inc-Key Competitors 21

Adamas Pharmaceuticals Inc-Key Employees 22

Adamas Pharmaceuticals Inc-Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Financial Announcements 24

Nov 02, 2018: Adamas reports third quarter 2018 financial results 24

Aug 02, 2018: Adamas announces second quarter 2018 financial results 26

May 03, 2018: Adamas Reports First Quarter 2018 Financial Results 27

Feb 22, 2018: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017 28

Nov 02, 2017: Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results 30

Aug 08, 2017: Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results 32

May 09, 2017: Adamas Reports Recent Achievements and First Quarter 2017 Financial Results 34

Feb 28, 2017: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016 35

Corporate Communications 37

Jun 28, 2017: Adamas Appoints New Chief Financial Officer 37

Apr 27, 2017: Adamas Pharmaceuticals appoints new COO 38

Product News 39

10/11/2017: Adamas Appoints Mardi C. Dier to its Board of Directors 39

09/13/2017: Adamas to Host Investor and Analyst Meeting on September 18, 2017 40

08/24/2017: Adamas Announces FDA Approval of GOCOVRI as First and Only Medication for the Treatment of Dyskinesia in Parkinson's Disease Patients 41

05/24/2018: Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI in Clinical Pharmacokinetics 42

04/27/2017: Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102 43

04/12/2018: Adamas Announces Data Presentations on GOCOVRI at The American Academy Of Neurology Annual Meeting 44

01/08/2018: Adamas Announces U.S. Commercial Launch of GOCOVRI the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinsons Disease Patients 46

01/08/2017: Adamas Pharma Outlines Key Business Priorities for 2017, Provides Update on ADS-5102 47

01/08/2017: Adamas Pharmaceuticals Outlines Key Business Priorities for 2017, Provides Update on ADS-4101 48

Product Approvals 49

Oct 25, 2017: FDA Recognizes Orphan Drug Exclusivity for Adamas' GOCOVRI 49

Jan 06, 2017: Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease 50

Clinical Trials 51

Jun 22, 2018: Adamas Presents New Data Analysis Demonstrating that GOCOVRI Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day 51

Apr 19, 2018: Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI in Parkinson's Disease Patients with Dyskinesia 52

Apr 12, 2018: Adamas Announces Data Presentations on ADS-4101 at The American Academy Of Neurology Annual Meeting 54

Apr 03, 2018: Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment 55

Mar 15, 2018: Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI in Parkinson Disease Patients with Dyskinesia 56

Feb 08, 2018: Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice 57

Feb 01, 2018: Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal 58

Sep 07, 2017: Adamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy 59

Jun 12, 2017: Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology 60

Jun 08, 2017: Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks 62

May 22, 2017: Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy 64

Apr 24, 2017: Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson's Disease 66

Apr 18, 2017: Adamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual Meeting 68

Mar 28, 2017: Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting 69

Feb 28, 2017: Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson's Disease and Movement Disorders Congress 70

Feb 17, 2017: Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017 71

Jan 03, 2017: Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy 72

Appendix 73

Methodology 73

About GlobalData 73

Contact Us 73

Disclaimer 73


List Of Figure

List of Figures

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adamas Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adamas Pharma Raises USD143.2 Million in Public Offering of Shares 11

Adamas Pharma Raises USD9.7 Million in Private Placement of Shares 13

Adamas Pharma Plans to Raise up to USD200 Million in Public Offering of Shares 14

Adamas Pharma Raises USD66 Million in Public Offering of Shares 15

Adamas Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 17

Adamas Pharma Completes IPO For USD 48 Million 18

Adamas Pharma Raises USD35 Million in Private Placement of 11% Royalty-Backed Note Due 2026 20

Adamas Pharmaceuticals Inc, Key Competitors 21

Adamas Pharmaceuticals Inc, Key Employees 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Adamas Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) is a pharmaceutical company that develops and commercializes therapeutics for chronic disorders of the central nervous system. The company's Gocovri, formerly ADS-5102, is an amantadine extended-release (XR) formulation for the treatment for dyskinesia in patients with Parkinson's disease. Gocovri is a high-dose, once-daily indication designed to deliver high level of amantadine in the morning and throughout the day when dyskinesia occurs. Its pipeline includes ADS-5102 for the treatment of wearing OFF, and delaying motor complications in Parkinson's disease; Huntington's chorea; tardive dyskinesia; non-motor disorders, including depression, and anti-psychotic induced weight gain; and Tourette syndrome; and various others indications; and ADS-4101 in Phase 3 for the treatment of partial onset seizures in patients with epilepsy. The company also offers namzaric and namenda XR for the treatment of moderate to severe Alzheimer's disease. Adamas Pharmaceuticals is headquartered in Emeryville, California, the US.

Adamas Pharmaceuticals Inc (ADMS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Equity Offering 11

Adamas Pharma Raises USD143.2 Million in Public Offering of Shares 11

Adamas Pharma Raises USD9.7 Million in Private Placement of Shares 13

Adamas Pharma Plans to Raise up to USD200 Million in Public Offering of Shares 14

Adamas Pharma Raises USD66 Million in Public Offering of Shares 15

Adamas Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 17

Adamas Pharma Completes IPO For USD 48 Million 18

Debt Offering 20

Adamas Pharma Raises USD35 Million in Private Placement of 11% Royalty-Backed Note Due 2026 20

Adamas Pharmaceuticals Inc-Key Competitors 21

Adamas Pharmaceuticals Inc-Key Employees 22

Adamas Pharmaceuticals Inc-Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Financial Announcements 24

Nov 02, 2018: Adamas reports third quarter 2018 financial results 24

Aug 02, 2018: Adamas announces second quarter 2018 financial results 26

May 03, 2018: Adamas Reports First Quarter 2018 Financial Results 27

Feb 22, 2018: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017 28

Nov 02, 2017: Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results 30

Aug 08, 2017: Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results 32

May 09, 2017: Adamas Reports Recent Achievements and First Quarter 2017 Financial Results 34

Feb 28, 2017: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016 35

Corporate Communications 37

Jun 28, 2017: Adamas Appoints New Chief Financial Officer 37

Apr 27, 2017: Adamas Pharmaceuticals appoints new COO 38

Product News 39

10/11/2017: Adamas Appoints Mardi C. Dier to its Board of Directors 39

09/13/2017: Adamas to Host Investor and Analyst Meeting on September 18, 2017 40

08/24/2017: Adamas Announces FDA Approval of GOCOVRI as First and Only Medication for the Treatment of Dyskinesia in Parkinson's Disease Patients 41

05/24/2018: Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI in Clinical Pharmacokinetics 42

04/27/2017: Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102 43

04/12/2018: Adamas Announces Data Presentations on GOCOVRI at The American Academy Of Neurology Annual Meeting 44

01/08/2018: Adamas Announces U.S. Commercial Launch of GOCOVRI the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinsons Disease Patients 46

01/08/2017: Adamas Pharma Outlines Key Business Priorities for 2017, Provides Update on ADS-5102 47

01/08/2017: Adamas Pharmaceuticals Outlines Key Business Priorities for 2017, Provides Update on ADS-4101 48

Product Approvals 49

Oct 25, 2017: FDA Recognizes Orphan Drug Exclusivity for Adamas' GOCOVRI 49

Jan 06, 2017: Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease 50

Clinical Trials 51

Jun 22, 2018: Adamas Presents New Data Analysis Demonstrating that GOCOVRI Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day 51

Apr 19, 2018: Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI in Parkinson's Disease Patients with Dyskinesia 52

Apr 12, 2018: Adamas Announces Data Presentations on ADS-4101 at The American Academy Of Neurology Annual Meeting 54

Apr 03, 2018: Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment 55

Mar 15, 2018: Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI in Parkinson Disease Patients with Dyskinesia 56

Feb 08, 2018: Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice 57

Feb 01, 2018: Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal 58

Sep 07, 2017: Adamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy 59

Jun 12, 2017: Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology 60

Jun 08, 2017: Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks 62

May 22, 2017: Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy 64

Apr 24, 2017: Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson's Disease 66

Apr 18, 2017: Adamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual Meeting 68

Mar 28, 2017: Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting 69

Feb 28, 2017: Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson's Disease and Movement Disorders Congress 70

Feb 17, 2017: Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017 71

Jan 03, 2017: Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy 72

Appendix 73

Methodology 73

About GlobalData 73

Contact Us 73

Disclaimer 73


List Of Figure

List of Figures

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adamas Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adamas Pharma Raises USD143.2 Million in Public Offering of Shares 11

Adamas Pharma Raises USD9.7 Million in Private Placement of Shares 13

Adamas Pharma Plans to Raise up to USD200 Million in Public Offering of Shares 14

Adamas Pharma Raises USD66 Million in Public Offering of Shares 15

Adamas Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 17

Adamas Pharma Completes IPO For USD 48 Million 18

Adamas Pharma Raises USD35 Million in Private Placement of 11% Royalty-Backed Note Due 2026 20

Adamas Pharmaceuticals Inc, Key Competitors 21

Adamas Pharmaceuticals Inc, Key Employees 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Adamas Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.